A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the relative dose intensity (RDI) of intravenous (IV)
CMF on a Day 1 and 8 schedule given every 28 days with pegfilgrastim support in subjects with
stage I-III breast cancer.